Merz Pharma

merz.com

With approximately 3,000 employees and 34 subsidiaries worldwide, Merz has evolved as a leading provider of aesthetics and special neurology. Privately held for more than 100 years, the company is distinguished by its innovative in-house R&D, solid financial strength and the right strategy for long-term growth.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

ERS GENOMICS AND LEPTON PHARMACEUTICALS LTD ENTER CRISPR/CAS9 LICENSE AGREEMENT

ERS Genomics | July 27, 2022

news image

ERS Genomics Limited is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD. This is a non-exclusive licensing agreement granting Lepton access to the ERS CRISPR/Cas9 patent portfolio for certain applications. ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Over 90 patents are held in over eighty countries. Lepton Pharmaceutical LTD...

Read More

Pharmacy Market

PFIZER COMPLETES ACQUISITION OF BIOHAVEN PHARMACEUTICALS

Pfizer and Biohaven Pharmaceuticals | October 04, 2022

news image

Pfizer Inc. announced the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults. The acquisition brings to Pfizer a portfolio of promising calcitonin gene-related peptide receptor antagonists including Rimegepant Approved in the United States under the trade name NURTEC® ODT, ...

Read More

Business Insights

PACK4U ACQUIRES LEADING PHARMACY TECHNOLOGY COMPANY CATALYST HEALTHCARE

Pack4U | January 07, 2022

news image

Pack4U, a connected health services company, acquires long-time technology partner Catalyst Healthcare whose patented AdhereNet® platform links pharmacists, patients, and care teams to effectively manage drug complexity and improve medication adherence. "We are dedicated to improving patient outcomes at scale. Bringing this domain knowledge in-house is vital for Pack4U. Catalyst's CEO Shane Bishop is a pharmacy thought leader and we are excited a...

Read More

VIEWS AND ANALYSIS, PHARMACY MARKET

SOLIGENIX INITIATES PHASE 2 CLINICAL TRIAL OF SGX302 (SYNTHETIC HYPERICIN) FOR THE TREATMENT OF MILD-TO-MODERATE PSORIASIS

Soligenix, Inc. | December 20, 2022

news image

Soligenix, Inc. a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that patient enrollment has been opened for its Phase 2a study evaluating SGX302 in the treatment of mild-to-moderate psoriasis. Psoriasis is an ongoing unmet medical need, with as many as 7.5 million people in the U.S. and 60-125 million people worldwide affected by this incurable disease. ...

Read More
news image

Business Insights

ERS GENOMICS AND LEPTON PHARMACEUTICALS LTD ENTER CRISPR/CAS9 LICENSE AGREEMENT

ERS Genomics | July 27, 2022

ERS Genomics Limited is pleased to announce a new license agreement with Lepton Pharmaceuticals LTD. This is a non-exclusive licensing agreement granting Lepton access to the ERS CRISPR/Cas9 patent portfolio for certain applications. ERS, co-founded by Dr. Emmanuelle Charpentier, 2020 Nobel Prize winner for gene-editing, provides access to the foundational CRISPR/Cas9 intellectual property. Over 90 patents are held in over eighty countries. Lepton Pharmaceutical LTD...

Read More
news image

Pharmacy Market

PFIZER COMPLETES ACQUISITION OF BIOHAVEN PHARMACEUTICALS

Pfizer and Biohaven Pharmaceuticals | October 04, 2022

Pfizer Inc. announced the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults. The acquisition brings to Pfizer a portfolio of promising calcitonin gene-related peptide receptor antagonists including Rimegepant Approved in the United States under the trade name NURTEC® ODT, ...

Read More
news image

Business Insights

PACK4U ACQUIRES LEADING PHARMACY TECHNOLOGY COMPANY CATALYST HEALTHCARE

Pack4U | January 07, 2022

Pack4U, a connected health services company, acquires long-time technology partner Catalyst Healthcare whose patented AdhereNet® platform links pharmacists, patients, and care teams to effectively manage drug complexity and improve medication adherence. "We are dedicated to improving patient outcomes at scale. Bringing this domain knowledge in-house is vital for Pack4U. Catalyst's CEO Shane Bishop is a pharmacy thought leader and we are excited a...

Read More
news image

VIEWS AND ANALYSIS, PHARMACY MARKET

SOLIGENIX INITIATES PHASE 2 CLINICAL TRIAL OF SGX302 (SYNTHETIC HYPERICIN) FOR THE TREATMENT OF MILD-TO-MODERATE PSORIASIS

Soligenix, Inc. | December 20, 2022

Soligenix, Inc. a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that patient enrollment has been opened for its Phase 2a study evaluating SGX302 in the treatment of mild-to-moderate psoriasis. Psoriasis is an ongoing unmet medical need, with as many as 7.5 million people in the U.S. and 60-125 million people worldwide affected by this incurable disease. ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us